BioSpace News Archive

NeuroOne Medical Technologies Corporation announced that, effective April 21, 2023, the Compensation Committee of the Board of Directors approved an equity award under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan, as a material inducement to one individual entering into employment with the Company.

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

Cooler Heads, a health tech company that has developed an FDA-cleared, portable patient-administered scalp cooling device to help cancer patients undergoing chemotherapy keep their hair, reports accelerated sales growth during its first year on the market.

IDEAYA Biosciences, Inc. announced the closing of its underwritten public offering of 8,858,121 shares of its common stock at a public offering price of $18.50 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 2,020,270 shares of common stock at a public offering price of $18.4999 per pre-funded warrant, before underwriting discounts and commissions.

Amgen announced financial results for the first quarter of 2023.

Nevro Corp. announced on April 24, 2023, the Board of Director of Nevro granted restricted stock unit awards covering an aggregate of 135,623 shares of its common stock and performance unit awards covering 135,623 shares of its common stock to Kevin Thornal, who joined Nevro as its Chief Executive Officer & President, in connection with his commencement of employment.

DexCom, Inc. reported its financial results as of and for the quarter ended March 31, 2023.

CooperCompanies announced it will report second quarter 2023 financial results on Thursday, June 1, 2023, at 4:15 PM ET.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2023.